What's in ibrahim doğru's pipeline?

ibrahim doğru has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ibrahim doğru's portfolio?

Top competitors by shared drug class: Cape Fear Valley Health System, Kavaklıdere Umut Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ibrahim-do-ru.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

ibrahim doğru — Portfolio Competitive Intelligence Brief

ibrahim doğru pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Naproxen Sodium + Codeine Phosphate	Naproxen Sodium + Codeine Phosphate	marketed	NSAID + opioid analgesic combination	COX-1, COX-2, mu-opioid receptor	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Cape Fear Valley Health System · 1 shared drug class
Kavaklıdere Umut Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ibrahim doğru:

Cite this brief

Drug Landscape (2026). ibrahim doğru — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ibrahim-do-ru. Accessed 2026-05-15.